These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32194288)

  • 1. Risk Factors, Clinical Outcomes, and Cost-of-Care Related to Graft Failure in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients.
    Wobma H; Jin Z; Moscoso S; Bhatia M; Broglie L; George D; Garvin J; Satwani P
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1318-1325. PubMed ID: 32194288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure.
    Lund TC; Liegel J; Bejanyan N; Orchard PJ; Cao Q; Tolar J; Brunstein C; Wagner JE; Verneris MR; Weisdorf D
    Am J Hematol; 2015 Oct; 90(10):892-6. PubMed ID: 26149534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence, Management, and Prognosis of Graft Failure and Autologous Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation.
    Park JH; Lee JH; Lee JH; Park HS; Choi EJ; Kang YA; Kang H; Woo JM; Lee YS; Jeon M; Lee KH
    J Korean Med Sci; 2021 Jun; 36(23):e151. PubMed ID: 34128593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
    Marsh RA; Rao MB; Gefen A; Bellman D; Mehta PA; Khandelwal P; Chandra S; Jodele S; Myers KC; Grimley M; Dandoy C; El-Bietar J; Kumar AR; Leemhuis T; Zhang K; Bleesing JJ; Jordan MB; Filipovich AH; Davies SM
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1460-70. PubMed ID: 25865646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients.
    Bhatt ST; Bednarski JJ; Berg J; Trinkaus K; Murray L; Hayashi R; Schulz G; Hente M; Grimley M; Chan KW; Kamani N; Jacobsohn D; Nieder M; Hale G; Yu L; Adams R; Dalal J; Pulsipher MA; Haut P; Chaudhury S; Davis J; Jaroscak J; Andreansky M; Willert J; Shenoy S
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):556-561. PubMed ID: 30321596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Umbilical Cord Blood Transplantation after Graft Failure from a Previous Hematopoietic Stem Cell Transplantation.
    Volt F; Ruggeri A; Scigliuolo GM; de Latour RP; Bierings M; Al-Seraihy A; Bittencourt H; Labussière-Wallet H; Rocha V; Kenzey C; Cappelli B; Rafii H; Gluckman E; Guerino-Cunha RL
    Transplant Cell Ther; 2022 Jan; 28(1):46.e1-46.e7. PubMed ID: 34757218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
    Chhabra S; Ahn KW; Hu ZH; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
    Blood Adv; 2018 Nov; 2(21):2922-2936. PubMed ID: 30396912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed chimerism and graft loss in pediatric recipients of an alemtuzumab-based reduced-intensity conditioning regimen for non-malignant disease.
    Oshrine BR; Olson TS; Bunin N
    Pediatr Blood Cancer; 2014 Oct; 61(10):1852-9. PubMed ID: 24939325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-myeloablative conditioning for second hematopoietic cell transplantation for graft failure in patients with non-malignant disorders: a prospective study and review of the literature.
    Mallhi K; Orchard PJ; Miller WP; Cao Q; Tolar J; Lund TC
    Bone Marrow Transplant; 2017 May; 52(5):726-732. PubMed ID: 28092353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
    Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
    Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
    van Besien K; Hari P; Zhang MJ; Liu HT; Stock W; Godley L; Odenike O; Larson R; Bishop M; Wickrema A; Gergis U; Mayer S; Shore T; Tsai S; Rhodes J; Cushing MM; Korman S; Artz A
    Haematologica; 2016 May; 101(5):634-43. PubMed ID: 26869630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.
    Geerlinks AV; Scull B; Krupski C; Fleischmann R; Pulsipher MA; Eapen M; Connelly JA; Bollard CM; Pai SY; Duncan CN; Kean LS; Baker KS; Burroughs LM; Andolina JR; Shenoy S; Roehrs P; Hanna R; Talano JA; Schultz KR; Stenger EO; Lin H; Zoref-Lorenz A; McClain KL; Jordan MB; Man TK; Allen CE; Marsh RA
    Blood Adv; 2023 Jul; 7(14):3725-3734. PubMed ID: 37042921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning.
    Robin M; Raj K; Chevret S; Gauthier J; de Lavallade H; Michonneau D; McLornan D; Peffault de Latour R; Potter V; Kulasekararaj A; Sicre de Fontbrune F; Pagliuca A; Yakoub-Agha I; Socié G; Mufti GJ
    Eur J Haematol; 2018 Oct; 101(4):466-474. PubMed ID: 29714032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders.
    Madden LM; Hayashi RJ; Chan KW; Pulsipher MA; Douglas D; Hale GA; Chaudhury S; Haut P; Kasow KA; Gilman AL; Murray LM; Shenoy S
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1467-1472. PubMed ID: 27164064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.
    Guru Murthy GS; Hari PN; Szabo A; Pasquini M; Narra R; Khan M; Abedin S; Chhabra S; Dhakal B; D'Souza A; Drobyski WR; Rizzo JD; Runaas L; Shah NN; Shaw B; Saber W; Fenske T; Hamadani M
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):827-833. PubMed ID: 30572109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics.
    Keklik F; Alrawi EB; Cao Q; Bejanyan N; Rashidi A; Lazaryan A; Arndt P; Dincer EH; Bachanova V; Warlick ED; MacMillan ML; Arora M; Miller J; Brunstein CG; Weisdorf DJ; Ustun C
    Haematologica; 2018 Dec; 103(12):2109-2115. PubMed ID: 30076172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research.
    Verneris MR; Lee SJ; Ahn KW; Wang HL; Battiwalla M; Inamoto Y; Fernandez-Vina MA; Gajewski J; Pidala J; Munker R; Aljurf M; Saber W; Spellman S; Koreth J
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1783-9. PubMed ID: 26055300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.